169 related articles for article (PubMed ID: 23826416)
21. Proangiogenic signature in advanced laryngeal carcinoma after microRNA expression profiling.
Popov TM; Giragosyan S; Petkova V; Stancheva G; Marinov T; Belitova M; Rangachev J; Popova D; Kaneva RP
Mol Biol Rep; 2020 Jul; 47(7):5651-5655. PubMed ID: 32533400
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.
Zhou M; Liu Z; Zhao Y; Ding Y; Liu H; Xi Y; Xiong W; Li G; Lu J; Fodstad O; Riker AI; Tan M
J Biol Chem; 2010 Jul; 285(28):21496-507. PubMed ID: 20460378
[TBL] [Abstract][Full Text] [Related]
23. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
[TBL] [Abstract][Full Text] [Related]
24. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.
Wu G; Qin XQ; Guo JJ; Li TY; Chen JH
Int J Clin Exp Pathol; 2014; 7(4):1449-58. PubMed ID: 24817940
[TBL] [Abstract][Full Text] [Related]
25. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
Chen Q; Xia HW; Ge XJ; Zhang YC; Tang QL; Bi F
Asian Pac J Cancer Prev; 2013; 14(12):7421-6. PubMed ID: 24460313
[TBL] [Abstract][Full Text] [Related]
26. Global microRNA expression profile in laryngeal carcinoma unveils new prognostic biomarkers and novel insights into field cancerization.
Popov TM; Stancheva G; Kyurkchiyan SG; Petkova V; Panova S; Kaneva RP; Popova DP
Sci Rep; 2022 Oct; 12(1):17051. PubMed ID: 36224266
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
28. DNA microarray reveals different pathways responding to paclitaxel and docetaxel in non-small cell lung cancer cell line.
Che CL; Zhang YM; Zhang HH; Sang YL; Lu B; Dong FS; Zhang LJ; Lv FZ
Int J Clin Exp Pathol; 2013; 6(8):1538-48. PubMed ID: 23923072
[TBL] [Abstract][Full Text] [Related]
29. Expression of miR-296-5p as predictive marker for radiotherapy resistance in early-stage laryngeal carcinoma.
Maia D; de Carvalho AC; Horst MA; Carvalho AL; Scapulatempo-Neto C; Vettore AL
J Transl Med; 2015 Aug; 13():262. PubMed ID: 26264462
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
Li X; Han X; Wei P; Yang J; Sun J
Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).
Liu Y; Gao S; Chen X; Liu M; Mao C; Fang X
Tumour Biol; 2016 Sep; 37(9):12231-12239. PubMed ID: 27236538
[TBL] [Abstract][Full Text] [Related]
33. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1.
Huang X; Qin J; Lu S
Int J Clin Exp Pathol; 2015; 8(2):1515-24. PubMed ID: 25973036
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells.
Zheng H; Wang JJ; Yang XR; Yu YL
World J Gastroenterol; 2020 Feb; 26(5):499-513. PubMed ID: 32089626
[TBL] [Abstract][Full Text] [Related]
36. Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.
Tao WY; Liang XS; Liu Y; Wang CY; Pang D
Int J Biol Sci; 2015; 11(1):48-58. PubMed ID: 25552929
[TBL] [Abstract][Full Text] [Related]
37. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.
Fujita Y; Kojima T; Kawakami K; Mizutani K; Kato T; Deguchi T; Ito M
Prostate; 2015 Oct; 75(14):1568-78. PubMed ID: 26074357
[TBL] [Abstract][Full Text] [Related]
38. miR-339-5p downregulation contributes to Taxol resistance in small-cell lung cancer by targeting α1,2-fucosyltransferase 1.
Gan CZ; Li G; Luo QS; Li HM
IUBMB Life; 2017 Nov; 69(11):841-849. PubMed ID: 28940895
[TBL] [Abstract][Full Text] [Related]
39. Potential using of microRNA-34A in combination with paclitaxel in colorectal cancer cells.
Soltani-Sedeh H; Irani S; Mirfakhraie R; Soleimani M
J Cancer Res Ther; 2019; 15(1):32-37. PubMed ID: 30880751
[TBL] [Abstract][Full Text] [Related]
40. [Expression of mir-21 and mir-375 in laryngeal squamous cell carcinoma].
Hu A; Jin X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Sep; 26(18):788-92. PubMed ID: 23259291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
